News from sysmex inostics gmbh A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages

Latest

27 Sep, 2019, 11:00 BST Sysmex Inostics Launches Two NGS-based Liquid Biopsy Panels for Cancer Therapy Drug Development

Sysmex Inostics announces the availability of the SafeSEQ Breast Cancer and Head and Neck Cancer Panels along with the SafeSEQ Rapid Custom...


04 Sep, 2019, 11:00 BST Sysmex Inostics Publishes First Feasibility Study of NGS-based Liquid Biopsy to Complement Early Breast Cancer Screening by Imaging

Using Sysmex Inostics' novel SafeSEQ next-generation sequencing cell-free DNA technology, investigators from the Biomedical Research Institute of...


02 Aug, 2019, 07:00 BST Sysmex Obtains Japanese Manufacturing and Marketing Approval for the First Blood-based RAS Mutation Testing for Colorectal Cancer

Sysmex Corporation has obtained Japanese manufacturing and marketing approval for the OncoBEAM™ RAS CRC Kit, used for blood-based circulating tumor...


18 Jul, 2019, 11:00 BST Liquid Biopsy Performance Comparison of Sysmex Inostics OncoBEAM RAS CRC and BioCartis Idylla ctKRAS Testing Published in Scientific Reports (Nature Journal)

Sysmex Inostics, a global leader in blood based circulating tumor DNA (ctDNA) analysis and molecular diagnostics for oncology, today announces...


30 May, 2019, 11:00 BST Sysmex Inostics OncoBEAM™-EGFR Digital PCR Liquid Biopsy Demonstrates Two-fold Higher Detection of p.T790M Mutations in 183 NSCLC Patients in Comparison Study

Sysmex Inostics announces the publication of clinical research conducted as part of the CIRculating CANcer (CIRCAN) Program at the Lyon Cancer...


28 May, 2019, 11:51 BST Sysmex Inostics' SafeSEQ ER+/HER2- Breast Cancer Panel Demonstrates Equivalent Sensitivity to OncoBEAM™ Enhanced Digital PCR Technology for Detection of Mutations in Circulating Tumor DNA

Recent data presented by Dr. Hope S. Rugo from the University of California San Francisco on behalf of investigators in the Translational Breast...


25 Feb, 2019, 11:00 GMT Sysmex Inostics' OncoBEAM™ Demonstrates Clinical Validity and Superior Performance Versus Pan-cancer NGS for Blood-based Mutation Detection for Hepatocellular Carcinoma

Data recently published in Clinical Cancer Research demonstrate the advantages of using an ultra-high sensitivity test for detection of mutations...


05 Nov, 2018, 11:00 GMT Sysmex Inostics OncoBEAM™ Circulating Tumor DNA Technology Demonstrates Superior Response Prediction for Advanced Pancreatic Cancer over Standard-of-care Protein Biomarkers

Recent data published in Annals of Oncology from a study conducted by Sysmex Inostics and University of Munich indicate that circulating tumor DNA...


18 Oct, 2018, 11:00 BST Sysmex Inostics' OncoBEAM™ Platform Demonstrates Superior Detection of Clinically-relevant Mutations for Therapy Selection and Molecular Monitoring for Lung and Colon Cancers

Data presented at the European Society of Medical Oncology (ESMO) 2018 meeting in Munich, Germany by three clinical oncology research groups...


15 Oct, 2018, 11:40 BST Sysmex Inostics' OncoBEAM™ Liquid Biopsy Technology Demonstrates Utility for Clinical Management of Melanoma Patients Undergoing Treatment With Targeted Therapy and Immune Checkpoint Inhibitors

Sysmex Inostics, a pioneer in blood-based circulating tumor DNA (ctDNA) analysis and molecular diagnostics for oncology, is pleased to announce...


28 Sep, 2018, 11:00 BST Sysmex Inostics Announces Launch of OncoBEAMTM EGFR Kit v2 (RUO) in Europe and Asia

Sysmex Inostics, a subsidiary of Sysmex Corporation and a global leader in blood-based circulating tumor DNA (ctDNA) analysis and molecular...


31 May, 2018, 11:00 BST Clinical Evaluation of Sysmex Inostics' Plasma NGS Liquid Biopsy Technology to Complement Mammography When Screening for Early Stage Breast Cancer Presented at the 2018 ASCO Annual Meeting

Sysmex Inostics, a global leader in blood based circulating tumor DNA (ctDNA) analysis, today announced that preliminary clinical results of a novel...


13 Apr, 2018, 11:00 BST Sysmex Inostics Expands OncoBEAM™ Liquid Biopsy Testing in the U.S. to Assist Clinicians and Patients

Sysmex Inostics, a subsidiary of Sysmex Corporation, a global leader in blood based circulating tumor DNA (ctDNA) analysis and molecular diagnostics...


11 Apr, 2018, 11:00 BST Sysmex Inostics: OncoBEAM™ RAS CRC Liquid Biopsy Test Now Reimbursed in Germany by BARMER

Colorectal cancer patients in Germany insured by BARMER are now covered for the OncoBEAM RAS CRC IVD Test, an innovative liquid biopsy diagnostic...


22 Jan, 2018, 11:00 GMT In Depth: Performance Comparison of OncoBEAM™ RAS CRC and Idylla™ ctKRAS Liquid Biopsy Testing for KRAS Mutation Detection Presented at ASCO GI 2018

Sysmex Inostics, a global leader in blood-based circulating tumor DNA (ctDNA) analysis and molecular diagnostics for oncology, today highlights...


17 Jan, 2018, 12:00 GMT Liquid Biopsy Performance Comparison of OncoBEAM RAS CRC and Idylla ctKRAS Testing Presented at ASCO GI 2018 Meeting

Sysmex Inostics, a global leader in blood based circulating tumor DNA (ctDNA) analysis and molecular diagnostics for oncology, today announces data...


21 Nov, 2017, 11:00 GMT Expert Taskforce Recommendation of OncoBEAM™ RAS CRC Liquid Biopsy Testing in Routine Clinical Practice for Colorectal Cancer Patients

Sysmex Inostics, a subsidiary of Sysmex Corporation, a global leader in blood based circulating tumor DNA (ctDNA) analysis and molecular diagnostics...


26 Sep, 2017, 11:00 BST OncoBEAM[TM] EGFR Kit (RUO) at Jessenius Medical Faculty of Comenius University and its University Hospital, in Martin, Slovakia

The launch is the first of its kind and will widen the use of of BEAMing technology in lung cancer area. Sysmex Inostics, a subsidiary of Sysmex...


05 Jul, 2016, 07:00 BST Sysmex Inostics Blood-based RAS Biomarker Test Now Available in Italy

Assessing RAS mutation status in patients with mCRC has shown that anti-epidermal growth factor receptor (EGFR) monoclonal antibody therapies can...


28 Jun, 2016, 07:00 BST Sysmex Inostics Announces the Opening of Its Global Training Center for the OncoBEAM™ Platform in Barcelona, Spain

Sysmex Inostics, a subsidiary of Sysmex Corporation, today announced the opening of a global OncoBEAM™ Training Center in Barcelona. The new...


25 May, 2016, 14:00 BST Sysmex Inostics Announces Key Clinical Data to be Presented at ASCO Annual Meeting 2016 - Abstract will be Included in the Best of ASCO® Program

Sysmex Inostics, a subsidiary of Sysmex Corporation, today announced that the company and its collaborators will present key performance data of its...


18 May, 2016, 07:00 BST Blood-based IVD RAS Biomarker Test Now Available in France

Sysmex Inostics, a subsidiary of Sysmex Corporation, today announced its first RAS biomarker testing site in France opening at the Biopathology...


06 Apr, 2016, 07:00 BST New Liquid Biopsy RAS Testing for Metastatic Colorectal Cancer Patients Now Available for Clinical Practices

Sysmex Inostics, a subsidiary of Sysmex Corporation, today announced that its OncoBEAM® RAS CRC test has been granted CE Mark approval. The test,...


15 Mar, 2016, 14:00 GMT Blood-based RAS Biomarker Test Now Available in Slovakia

Sysmex Inostics, a subsidiary of Sysmex Corporation, today announced its first RAS biomarker testing site in Slovakia opening at Martinské bioptické...


29 Feb, 2016, 14:00 GMT Sysmex Signs Supply and Distribution Agreement with Streck

Sysmex Inostics, a subsidiary of Sysmex Corporation, today announced that Sysmex Corporation has signed a worldwide supply and distribution agreement ...